Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

18 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-06

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic Obstructive Pulmonary Patients is a defined by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. It is associated with an atrophy of the skeletal muscle that impairs the patient's prognosis. The biological mechanisms of this muscle atrophy have not been elucidated, and the "spill-over theory" has recently emerged. Indeed, in COPD patients, the pulmonary inflammation is associated with a systemic low-grade inflammation, and the increased pro-inflamatory molelcules in the blood - which constitute the cellular micro-environement of the muscle fibre - could activate the mechanisms of the cell atrophy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Determinants of Lower Limb Muscle Atrophy Induced During an Hospitalization for Exacerbation of COPD

NCT03153826

Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Copd Muscle Atrophy

TERMINATED NA

Involvement of Nervous System in Muscle Weakness in COPD Patients

NCT01679782

Chronic Obstructive Pulmonary Disease

COMPLETED

Muscle Dysfunction in Patients With Chronic Obstructive Lung Disease (COPD): the Role of Sympathetic Activation

NCT01750489

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Identification of Explanatory Factors for the Lack of Muscle Strength Gain Following a Pulmonary Rehabilitation Program in COPD Patients

NCT06271122

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Mitochondrial Dysfunction and Oxidative Stress in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01183052

COPD Patients

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy subjects

Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old

Determination of pro-inflammatory plasma factors

Intervention Type OTHER

Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old

COPD patients

Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old

Determination of pro-inflammatory plasma factors

Intervention Type OTHER

Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Determination of pro-inflammatory plasma factors

Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

35 to 85 years old

* COPD patients: association of symtoms (breathlessness, cough, sputum) and chronic exposure to inhalated risk factors (like tobacco smoke) and a FEV1/VC ratio \<70% assessed by a spirometry
* Healthy subjects: A sedentariness assessed by a Voorrips score \<9.4 and/or a report of \<150 min/week of moderate-to-vigorous physical activity

Exclusion Criteria

* A recent COPD exacerbation (\< 4weeks)
* The decompensation of a comorbidity
* An antioxidant supplementation or medication
* A long-term systemic corticosteroid medication

Minimum Eligible Age

35 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes